Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | What does the future hold for dendrimer nanoparticles in solid tumors?

Jia (Jenny) Liu, MD, PhD, St Vincent’s Hospital, Sydney, Australia, gives an overview of potential integration of dendrimer-enhanced (DEP) SN38 (DEP irinotecan), which incorporates dendrimer nanoparticles, in the treatment of solid tumors. Following on from the Phase I/II trial (2019-001318-40), further Phase III trials may be conducted to compare it to irinotecan, especially in colorectal and ovarian cancer. Preclinical studies have additionally suggested synergy between dendrimer nanoparticles with checkpoint and PARP inhibitors, as well as radioligands and antibody-drug conjugates (ADCs). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.